Chemical Optimization of Cerebral Embolectomy 2 (CHOICE 2) trial: study protocol.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Renú Arturo, de la Riva Patricia, Delgado-Mederos Raquel, Dorado Laura, Fernandez-Couto Maria Dolores, Herrera-Isasi Maria, López Hernández Nicolás, Morales Ana, Morales-Caba Lluis, Camps-Renom Pol, Singla Alba, Terceño Mikel, Vega Pedro, Amaro Sergio, Blasco Jordi, Laredo Carlos, Leira Enrique C, Oleaga Laura, Serena Joaquin, Urra Xabier, Werner Mariano, Hernández Fernández Francisco, Valls Joan, Arenillas Lara Juan Francisco, Freijo Maria Del Mar, Pérez de la Ossa Natalia, San Roman Luis, Torres Ferran, Castellanos Mar, Davalos Antonio, Chamorro Angel, CHOICE 2 Investigators
Аннотация
AIM: The Chemical Optimization of Cerebral Embolectomy 2 (CHOICE 2) trial is designed to confirm whether adjunctive intra-arterial alteplase, administered after successful MT, improves clinical outcomes in patients with LVO stroke.
SAMPLE SIZE ESTIMATES: A total of 440 patients (220 per group) randomised in a 1:1 ratio to receive intra-arterial thrombolysis or not intra-arterial thrombolysis provides 80% statistical power to detect a 14% absolute benefit in the primary endpoint (the proportion of patients achieving modified Rankin Scale (mRS) 0-1 at 90 days), assuming a rate of 40% in the control group, a 5% two-sided type I error. The sample size also provides >95% power for detecting an 18% absolute benefit in secondary imaging endpoints, assuming a 58% rate in the control group.
METHODS AND DESIGN: Multicentre, randomised, open, blinded end-point assessment phase III trial. Eligible patients are adults (≥18 years) with symptomatic LVO who undergo MT with successful or complete reperfusion at end of the procedure. Patients in the intervention group will receive a 15 min intra-arterial infusion of alteplase (1.0 mg/mL, maximum dose 20 mg).
STUDY OUTCOMES: The primary outcome is the proportion of patients achieving excellent functional outcome (mRS 0-1) at 90 days. Key secondary outcomes are the presence of hypoperfusion on brain CT perfusion at 36±24 hours post randomisation, infarct expansion, Barthel Index and quality of life. Mortality and symptomatic intracerebral haemorrhage will also be evaluated.
DISCUSSION: This trial will provide evidence whether rescue intra-arterial thrombolysis improves clinical outcome in patients with LVO stroke who achieve successful or complete angiographic reperfusion following MT.